Below you will find a list of clinical trials currently open at Vista Oncology. We open and close trials frequently, so even if you do not see a trial for your cancer type on this list, ask your provider if there is one available for you.
Trials For Non-Hodgkin Lymphoma:
•CC-5013-NHL-008: MAGNIFY : A Phase 3b Randomized Study Of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed By Lenalidomide Single-Agent Maintenance versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
◦This is a trial for individuals with Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma, who have relapsed or progressed after first or second line therapy.
•UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
◦This is a trial for individuals with non-Hodgkin’s Lymphoma (Follicular Lymphoma, Small Lymphocytic Leukemia, Marginal Zone Lymphoma, or Diffuse Large B Cell Lymphoma) who have relapsed or progressed after first or second line therapy.
Trials for Hodgkin Lymphoma:
•CA209-812: CheckMate: Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivoluMab clinical Trial Evaluation 812)
◦This is a trial for those who have relapsed or progressed under several lines of therapy or those who are ineligible for a stem cell transplant.
Trials for Small Cell Lung Cancer:
•DIV-SCLC-301: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer
◦This is a trial for individuals with Small Cell Lung Cancer who have relapsed or progressed under first line platinum-based therapy.
Trials for Multiple Myeloma:
•Oncotherapeutics X10641: A phase 2 study of Ixazomib as a replacement for Bortezomib or Carfilzomib for multiple (MM) patients recently relapsed or refractory to their last combination regimen containing either Bortezomib or Carfilzomib
◦This is a trial for individuals with Multiple Myeloma who have previously relapsed or progressed under first line therapy containing either Bortezomib or Carfilzomib.
If you have any questions about participating in a clinical trial here at Vista Oncology or at another facility please ask your physician if you are eligible!